Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: pfisterer j. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66. doi: 10.1158/1078-0432.CCR-06-0691. Clin Cancer Res. 2007. PMID: 17255266
The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J. Riener EK, et al. Among authors: pfisterer j. Gynecol Oncol. 2004 Oct;95(1):89-94. doi: 10.1016/j.ygyno.2004.06.048. Gynecol Oncol. 2004. Retraction in: Gynecol Oncol. 2005 Mar;96(3):1021. doi: 10.1016/s0090-8258(05)00064-8 PMID: 15385115 Retracted. Clinical Trial.
Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Greimel ER, et al. Among authors: pfisterer j. J Clin Oncol. 2006 Feb 1;24(4):579-86. doi: 10.1200/JCO.2005.02.4067. J Clin Oncol. 2006. PMID: 16446330 Clinical Trial.
Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.
Fotopoulou C, duBois A, Karavas AN, Trappe R, Aminossadati B, Schmalfeldt B, Pfisterer J, Sehouli J; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Fotopoulou C, et al. Among authors: pfisterer j. J Clin Oncol. 2008 Jun 1;26(16):2683-9. doi: 10.1200/JCO.2008.16.1109. J Clin Oncol. 2008. PMID: 18509180
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany.
Pfisterer J, Du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F. Pfisterer J, et al. Int J Gynecol Cancer. 2009 Jan;19(1):109-15. doi: 10.1111/IGC.0b013e3181991a7c. Int J Gynecol Cancer. 2009. PMID: 19258951 Clinical Trial.
207 results